Given the deleterious effect of the DYRK2 protein on the stability of CML, a novel approach for LSC eradication based on DYRK2 protein stabilization was postulated14. The gene discussed is DYRK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.